Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stock Moving News

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Apr 09, 2021 7:21am

97 Views

Post# 32965134

RE:Stock Moving News

Did the clown re-enter and getting fomo?
Looking forward to the next you sell and starting bashing again.
Ill be sure to chronicle your posts and time stamp them for all to see. Lol!

Duster340 wrote: on the way soon folks.

*AME Study results (my guess before month end)

*Updated progress of the developement of new molecules (could be anytime)

*Evolution Summit may/11-13th

just a few near term catalysts that will move the stock price higher
glta